GlaxoSmithKline Inc.

Paladin Labs Inc.: Paladin Labs and GlaxoSmithKline Inc. Sign Agreement on Dexedrine(R) and Mark Start of a New Strategic Relationship

Market Wire - Pharmaceuticals and Biotech: Biotech (Free subscription) | 28/11/2008

MONTREAL, CANADA (MARKET WIRE) Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced it is signing an agreement with GlaxoSmithKline Inc. (GSK) and Glaxo Group Limited that appoints Paladin Labs Inc. as the exclusive distributor of Dexedrine(R) (dextroamphetamine sulfate) within Canada for a period of three years, with an option...

Paladin Labs and GlaxoSmithKline Inc. Sign Agreement on Dexedrine(R) and Mark Start of a New Strategic Relationship

The Earth Times Online Newspaper (Free subscription) | 28/11/2008

MONTREAL, CANADA -- 11/28/08 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced it is signing an agreement with GlaxoSmithKline Inc. (GSK) and Glaxo Group Limited that appoints Paladin Labs Inc. as..

Paladin Labs and GlaxoSmithKline Inc. Sign Agreement on Dexedrine(R) and Mark Start of a New Strategic Relationship

The Earth Times Online Newspaper (Free subscription) | 28/11/2008

MONTREAL, CANADA -- 11/28/08 -- Paladin Labs Inc. (TSX: PLB), a leading Canadian specialty pharmaceutical company, today announced it is signing an agreement with GlaxoSmithKline Inc. (GSK) and Glaxo Group Limited that appoints Paladin Labs Inc. as..

Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc.

Business Wire (Free subscription) | 11/11/2008

Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participações SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc. CHICAGO--()--Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include:...

• Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc. - The Earth Times Online Newspaper
• Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc. - The Earth Times Online Newspaper

Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc.

The Earth Times Online Newspaper (Free subscription) | 11/11/2008

CHICAGO - (Business Wire) Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sprint Nextel Corp. (NYSE: S), Ultrapar Participações SA (NYSE: UGP), Eurand N.V. (Nasdaq: EURX), Cephalon, Inc. (Nasdaq: CEPH) and...

Zacks Analyst Blog Highlights: Sprint Nextel Corp., Ultrapar Participacoes SA, Eurand N.V., Cephalon, Inc. and GlaxoSmithKline Inc.

The Earth Times Online Newspaper (Free subscription) | 11/11/2008

CHICAGO - (Business Wire) Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include: Sprint Nextel Corp. (NYSE: S), Ultrapar Participações SA (NYSE: UGP), Eurand N.V. (Nasdaq: EURX), Cephalon, Inc. (Nasdaq: CEPH) and...

Ban diabetes drug Avandia: consumer group to FDA

CBC.ca (Free subscription) | 31/10/2008

In November 2007, GlaxoSmithKline Inc., the manufacturer of rosiglitazone, updated its prescribing information in consultation with Health Canada after a study published in the New England Journal of Medicine reported a 43 per cent higher risk of heart attack for those taking rosiglitazone compared to people taking other diabetes drugs or no diabetes medication at all.

• Avandia Ban Calls Grow - Warnings Not Seen As Enough Warning - Press Releases
• Group wants ban on diabetes drug Avandia - News & Observer
• See the 14 articles on the same subject